• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA to make decision on Corium’s transdermal patch for treating dementia next year

October 12, 2021 By Sean Whooley

CoriumCorium (NSDQ:CORI) announced today that the FDA set a Prescription Drug User Fee (PDUFA) target action date for its Adlarity system.

The FDA set the PDUFA target action date for Adlarity (donepezil transdermal system), a transdermal patch designed to treat dementia or Alzheimer’s disease, for March 11, 2022.

If approved, Boston-based Corium’s once-weekly Adlarity patch formulation would be the company’s second central nervous system (CNS) therapy product approved for the U.S. market within the past year following the March approval of its once-daily Azstarys oral capsule for treating ADHD symptoms.

According to a news release, Corium’s proprietary Corplex technology enables transdermal therapeutics that incorporate small molecule drugs, like Adlarity, to be delivered through the skin. The company designed the transdermal patch for a seven-day wear with consistent adhesion, eliminating the daily need for an oral medication that may cause difficulties in patients with significant memory problems brought on by dementia or Alzheimer’s.

The FDA previously approved donepezil as a once-daily tablet and as an orally disintegrating tablet for treating mild, moderate or severe forms of the disease. Adlarity’s slow and steady release of the therapeutic regularly delivers the drug through the skin with a design meant to avoid gastrointestinal tract absorption and associated side effects.

Corium is currently pursuing approval of two transdermal Adlarity doses capable of delivering 5mg or 10mg of donepezil daily. The company also has its Corplex platform under development for delivering drugs to treat patients with other CNS conditions, diseases in other therapeutic areas and consumer products beyond those for which it is currently used.

“Having Adlarity under consideration by the FDA reflects the significant R&D expertise at Corium. With Adlarity, Corium has leveraged our innovative Corplex technology to improve the most commonly used first-line treatment for patients with Alzheimer’s,” Corium president & CEO Perry J. Sternberg said in the release. “Our team at Corium is committed to addressing the unmet treatment needs for the Alzheimer’s community and others impacted by CNS diseases by developing innovative medicines. We look forward to the FDA’s decision early next year.”

Filed Under: Business/Financial News, Drug-Device Combinations, Food & Drug Administration (FDA), Neurological, Pharmaceuticals, Regulatory/Compliance Tagged With: Corium, FDA

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS